The global infectious disease diagnostic market revenue was around US$ 21.67 billion in 2023 and is estimated to reach US$ 42.39 billion by 2032, growing at a compound annual growth rate (CAGR) of 7.8% during the forecast period from 2024 to 2032.
Infectious disease diagnostics involves different laboratory tests and techniques to determine and diagnose diseases or illnesses caused by pathogens such as viruses, bacteria, parasites, or fungi. Healthcare providers utilize a combination of physical examination, laboratory tests, medical history, imaging studies, serology, microscopy, point-of-care testing, contact tracing, and genomic sequencing to determine the cause of disease and develop an effective treatment plan.
Market Driving Factors
Emerging economies such as Brazil, India, Russia, Turkey, and South Africa are estimated to provide potential growth possibilities for key players operating in the market. This is mainly due to the large patient population, high disease prevalence, enhanced healthcare infrastructure, the surge in disposable income, and increasing medical tourism.
The increasing prevalence of infectious diseases is estimated to drive the market. This is due to diseases such as human immunodeficiency virus/Acquired immune deficiency syndrome, tuberculosis, sexually transmitted infections, hepatitis, and respiratory infections that need an accurate and timely diagnosis for sufficient treatment and control. As a result, early diagnosis of these diseases plays an important role in the monitoring of these infectious diseases.
The high price of cutting-edge diagnostic tests hinders market growth.
Regional Analysis
North America dominated the market in terms of the largest shares. This is due to the existence of well-established healthcare infrastructure and cutting-edge medical facilities in nations such as Canada and the United States. Furthermore, the surged prevalence of infectious diseases such as influenza, COVID-19, and others in the region has created a boosted demand for effective diagnosis and treatment choices.
The Asia Pacific is estimated to dominate the market in terms of growth rate. This is mainly owing to the high prevalence of infectious diseases in the region, especially in nations such as China, India, and Indonesia. Furthermore, the surging incidence of hepatitis, dengue fever, and malaria in these nations has led to a rising demand for effective diagnostic tools and techniques. In addition, the increasing awareness about the significance of early diagnosis and treatment of infectious diseases among healthcare specialists and patients is also contributing to boosting the market in the region.
Segmentation Insights
Product Insight
The kits, reagents, and consumables segment dominate the market in terms of the largest shares. This is mainly due to the surging prevalence of infectious diseases, which has led to an increase in demand for diagnostic tests, which in turn has boosted the sales of reagents, kits, and consumables. Furthermore, advances in molecular diagnostics have resulted in the development of unique and innovative assays that need specialized reagents and consumables is estimated to drive the segment growth.
Type of Testing Insight
The laboratory testing segment dominates the market in terms of the largest shares. This is mainly due to its important role in monitoring and detecting several infectious diseases. In addition, laboratory tests are crucial for diagnosing and controlling infectious diseases, as they offer accurate and reliable outcomes that enable healthcare experts to make informed decisions regarding patient care and treatment.
Disease Type Insight
The COVID-19 segment dominated the market in terms of revenue. This can be attributed by the unprecedented pandemic scale and the urgent requirement for accurate and immediate diagnosis of the virus. For instance, according to the World Health Organization statistics, there were approximately 773.8 million COVID-19 cases globally. As a result, there was an increase in demand for diagnostic tests, including antibody tests, polymerase chain reaction (PCR) tests, and immediate antigen tests. Additionally, the development of vaccines and treatments for COVID-19 has also boosted the market expansion.
Prominent Companies
Segmentation Outline
The global infectious disease diagnostic market segmentation focuses on the Product, Type of Testing, Technology, Disease Type, End User, and Region.
By Product
By Type of Testing
By Technology
By Disease Type
By End User
By Region
[TABLE OF CONTENTS]
1 INTRODUCTION OF GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET
1.1 OVERVIEW OF THE MARKET
1.2 SCOPE OF REPORT
1.3 ASSUMPTIONS
2 EXECUTIVE SUMMARY: INFECTIOUS DISEASE DIAGNOSTIC MARKET
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 VALIDATION
3.3 PRIMARY INTERVIEWS
3.4 LIST OF DATA SOURCES
3.5 ANALYST TOOLS AND MODELS
4 GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET OUTLOOK
4.1 OVERVIEW
4.2 MARKET DYNAMICS AND TRENDS
4.2.1 DRIVERS
4.2.2 RESTRAINTS
4.2.3 OPPORTUNITIES
4.3 PORTERS FIVE FORCE ANALYSIS
4.4 VALUE CHAIN ANALYSIS
4.5 MARKET GROWTH AND OUTLOOK
4.5.1 PRICE TREND ANALYSIS
4.5.2 OPPORTUNITY SHARE
5 GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY PRODUCT
5.1 OVERVIEW
5.2 REAGENTS, KITS, AND CONSUMABLES
5.3 INSTRUMENTS
5.4 SOFTWARE AND SERVICES
6 GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TYPE OF TESTING
6.1 OVERVIEW
6.2 LABORATORY TESTING
6.3 POC TESTING
7 GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY TECHNOLOGY
7.1 OVERVIEW
7.2 CLINICAL MICROBIOLOGY
7.3 DNA MICROARRAY
7.4 DNA SEQUENCING AND NEXT-GENERATION SEQUENCING
7.5 IMMUNODIAGNOSTICS
7.6 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
7.7 POLYMERASE CHAIN REACTION
7.8 OTHERS
8 GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY DISEASE TYPE
8.1 OVERVIEW
8.2 COVID-19
8.3 HEPATITIS
8.4 HIV
8.5 HOSPITAL-ACQUIRED INFECTIONS
8.6 HPV
8.7 INFLUENZA
8.8 MOSQUITO-BORNE DISEASES
8.9 SYPHILIS
8.10 OTHERS
9 GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY END USER
9.1 OVERVIEW
9.2 ACADEMIC RESEARCH INSTITUTES
9.3 DIAGNOSTICS LABORATORIES
9.4 HOSPITALS AND CLINICS
9.5 OTHERS
10 GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, BY GEOGRAPHY
10.1 OVERVIEW
10.2 NORTH AMERICA
10.2.1 NORTH AMERICA MARKET SNAPSHOT
10.2.2 U.S.
10.2.3 CANADA
10.2.4 MEXICO
10.3 EUROPE
10.3.1 EUROPE MARKET SNAPSHOT
10.3.2 WESTERN EUROPE
10.3.2.1 THE UK
10.3.2.2 GERMANY
10.3.2.3 FRANCE
10.3.2.4 ITALY
10.3.2.5 SPAIN
10.3.2.6 REST OF WESTERN EUROPE
10.3.3 EASTERN EUROPE
10.3.3.1 POLAND
10.3.3.2 RUSSIA
10.3.3.3 REST OF EASTERN EUROPE
10.4 ASIA PACIFIC
10.4.1 ASIA PACIFIC MARKET SNAPSHOT
10.4.2 CHINA
10.4.3 JAPAN
10.4.4 INDIA
10.4.5 AUSTRALIA & NEW ZEALAND
10.4.6 ASEAN
10.4.7 REST OF ASIA PACIFIC
10.5 MIDDLE EAST & AFRICA
10.5.1 MIDDLE EAST & AFRICA MARKET SNAPSHOT
10.5.2 UAE
10.5.3 SAUDI ARABIA
10.5.4 SOUTH AFRICA
10.5.5 REST OF MEA
10.6 SOUTH AMERICA
10.6.1 SOUTH AMERICA MARKET SNAPSHOT
10.6.2 BRAZIL
10.6.3 ARGENTINA
10.6.4 REST OF SOUTH AMERICA
11 GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 COMPANY MARKET RANKING
11.3 KEY DEVELOPMENT STRATEGIES
11.4 COMPETITIVE DASHBOARD
11.5 PRODUCT MAPPING
11.6 TOP PLAYER POSITIONING, 2022
11.7 COMPETITIVE HEATMAP
11.8 TOP WINNING STRATEGIES
12 COMPANY PROFILES
12.1 ABBOTT
12.1.1 OVERVIEW
12.1.2 FINANCIAL PERFORMANCE
12.1.3 PRODUCT OUTLOOK
12.1.4 KEY DEVELOPMENTS
12.1.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.2 BECTON DICKINSON
12.2.1 OVERVIEW
12.2.2 FINANCIAL PERFORMANCE
12.2.3 PRODUCT OUTLOOK
12.2.4 KEY DEVELOPMENTS
12.2.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.3 BIOMÉRIEUX
12.3.1 OVERVIEW
12.3.2 FINANCIAL PERFORMANCE
12.3.3 PRODUCT OUTLOOK
12.3.4 KEY DEVELOPMENTS
12.3.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.4 BIO-RAD LABORATORIES
12.4.1 OVERVIEW
12.4.2 FINANCIAL PERFORMANCE
12.4.3 PRODUCT OUTLOOK
12.4.4 KEY DEVELOPMENTS
12.4.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.5 CEPHEID
12.5.1 OVERVIEW
12.5.2 FINANCIAL PERFORMANCE
12.5.3 PRODUCT OUTLOOK
12.5.4 KEY DEVELOPMENTS
12.5.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.6 DANAHER
12.6.1 OVERVIEW
12.6.2 FINANCIAL PERFORMANCE
12.6.3 PRODUCT OUTLOOK
12.6.4 KEY DEVELOPMENTS
12.6.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.7 F. HOFFMANN-LA ROCHE LTD
12.7.1 OVERVIEW
12.7.2 FINANCIAL PERFORMANCE
12.7.3 PRODUCT OUTLOOK
12.7.4 KEY DEVELOPMENTS
12.7.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.8 HOLOGIC INC.
12.8.1 OVERVIEW
12.8.2 FINANCIAL PERFORMANCE
12.8.3 PRODUCT OUTLOOK
12.8.4 KEY DEVELOPMENTS
12.8.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.9 LUMINEX CORPORATION
12.9.1 OVERVIEW
12.9.2 FINANCIAL PERFORMANCE
12.9.3 PRODUCT OUTLOOK
12.9.4 KEY DEVELOPMENTS
12.9.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.10 QIAGEN INC.
12.10.1 OVERVIEW
12.10.2 FINANCIAL PERFORMANCE
12.10.3 PRODUCT OUTLOOK
12.10.4 KEY DEVELOPMENTS
12.10.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
12.11 THERMO FISHER SCIENTIFIC INC.
12.11.1 OVERVIEW
12.11.2 FINANCIAL PERFORMANCE
12.11.3 PRODUCT OUTLOOK
12.11.4 KEY DEVELOPMENTS
12.11.5 KEY STRATEGIC MOVES AND DEVELOPMENTS
01
お客様のニーズに合わせてレポートをカスタマイズ可能
02
ベテランの市場調査員による専門的な分析
03
安全で簡単に利用できるオンライン決済方法
04
お客様のご要望に応じて、特定の章を購入することができます。
05
すべてのレポートに専門的な日本語翻訳を提供
06
包括的でわかりやすいレポートを迅速にお届けします。
07
購入後も継続的なサポートとアップデートが受けられます。
We Accept
Copyright ©2022 All rights reserved